Molecular diagnostics in chronic lymphocytic leukemia – Pathogenetic and clinical implications

References

• Chiorazzi N, Rai K R, Ferrarini M. Chronic lymphocytic leukaemia. N Engl J Med 2005; 352: 804–815
   PubMed Web of Science ®Google Scholar
• Montserrat E. New prognostic markers in CLL. Hematol Am Soc Hematol Educ Program 2006; 279–284
   PubMedGoogle Scholar
• Juliusson G, Oscier D G, Fitchett M, Ross F M, Stockdill G, Mackie M J, et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med 1990; 323: 720–724
   PubMed Web of Science ®Google Scholar
• Mayr C, Speicher M R, Kofler D M, Buhmann R, Strehl J, Busch R, et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 2006; 107: 742–751
   PubMed Web of Science ®Google Scholar
• Dicker F, Schnittger S, Haferlach T, Kern W, Schoch C. Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: a study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood 2006; 108: 3152–3160
   PubMed Web of Science ®Google Scholar
• Haferlach C, Dicker F, Schnittger S, Kern W, Haferlach T. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia 2007; 21: 2442–2451
   PubMed Web of Science ®Google Scholar
• Döhner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukaemia. N Engl J Med 2000; 343: 1910–1916
   PubMed Web of Science ®Google Scholar
• Krober A, Bloehdorn J, Hafner S, Buhler A, Seiler T, Kienle D, et al. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol 2006; 24: 969–975
   PubMed Web of Science ®Google Scholar
• Catovsky D, Richards S, Matutes E, Oscier D, Dyer M JS, Bezares R F, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. The Lancet 2007; 370: 230–239
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Winkler D, Bühler A, Zenz T, Groner S, Busch R, et al. Subcutaneous alemtuzumab (MabCampath) in fludarabine-refractory CLL (CLL2H Trial of the GCLLSG). Blood 2007; 118: 918A, (#3120)
   Google Scholar
• Döhner H, Stilgenbauer S, James M R, Benner A, Weilguni T, Bentz M, et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukaemia characterized by extensive nodal involvement and inferior prognosis. Blood 1997; 89: 2516–2522
   PubMed Web of Science ®Google Scholar
• Döhner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukaemias. Blood 1995; 85: 1580–1589
   PubMed Web of Science ®Google Scholar
• Keating M J, Flinn I, Jain V, Binet J L, Hillmen P, Byrd J, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554–3561
   PubMed Web of Science ®Google Scholar
• Grever M R, Lucas D M, Johnson A J, Byrd J C. Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia. Best Pract Res Clin Haematol 2007; 20: 545–556
   PubMed Web of Science ®Google Scholar
• Schwaenen C, Nessling M, Wessendorf S, Salvi T, Wrobel G, Radlwimmer B, et al. Automated array-based genomic profiling in chronic lymphocytic leukemia: development of a clinical tool and discovery of recurrent genomic alterations. Proc Natl Acad Sci USA 2004; 101: 1039–1044
   PubMed Web of Science ®Google Scholar
• Pfeifer D, Pantic M, Skatulla I, Rawluk J, Kreutz C, Martens U M, et al. Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays. Blood 2007; 109: 1202–1210
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Alizadeh A A, Widhopf G, Simon R, Davis R E, Yu X, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukaemia. J Exp Med 2001; 194: 1639–1647
   PubMed Web of Science ®Google Scholar
• Klein U, Tu Y, Stolovitzky G A, Mattioli M, Cattoretti G, Husson H, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001; 194: 1625–1638
   PubMed Web of Science ®Google Scholar
• Haslinger C, Schweifer N, Stilgenbauer S, Dohner H, Lichter P, Kraut N, et al. Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. J Clin Oncol 2004; 22: 3937–3949
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Chuang E Y, Davis R E, Wiestner A, Alizadeh A A, Arthur D C, et al. Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood 2004; 104: 1428–1434
   PubMed Web of Science ®Google Scholar
• Vallat L D, Park Y, Li C, Gribben J G. Temporal genetic program following B-cell receptor cross-linking: altered balance between proliferation and death in healthy and malignant B cells. Blood 2007; 109: 3989–3997
   PubMed Web of Science ®Google Scholar
• Rodriguez A, Villuendas R, Yanez L, Gomez M E, Diaz R, Pollan M, et al. Molecular heterogeneity in chronic lymphocytic leukemia is dependent on BCR signaling: clinical correlation. Leukemia 2007; 21: 1984–1991
   PubMed Web of Science ®Google Scholar
• Calin G A, Dumitru C D, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 15524–15529
   PubMed Web of Science ®Google Scholar
• Calin G A, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik S E, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 27(353)1793–1801
   Web of Science ®Google Scholar
• Borkhardt A, Fuchs U, Tuschl T. MicroRNA in chronic lymphocytic leukemia. N Engl J Med 2006; 354: 524–525
   PubMed Web of Science ®Google Scholar
• Fulci V, Chiaretti S, Goldoni M, Azzalin G, Carucci N, Tavolaro S, et al. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood 2007; 109: 4944–4951
   PubMed Web of Science ®Google Scholar
• He L, He X, Lowe S W, Hannon G J. microRNAs join the p53 network – another piece in the tumour-suppression puzzle. Nat Rev Cancer 2007; 7: 819–822
   PubMed Web of Science ®Google Scholar
• He L, He X, Lim L P, de Stanchina E, Xuan Z, Liang Y, et al. A microRNA component of the p53 tumour suppressor network. Nature 2007; 447: 1130–1134
   PubMed Web of Science ®Google Scholar
• Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007; 8: 286–298
   PubMed Web of Science ®Google Scholar
• Smith L T, Otterson G A, Plass C. Unraveling the epigenetic code of cancer for therapy. Trends Genetics 2007; 23: 449–456
   PubMed Web of Science ®Google Scholar
• Jenuwein T, Allis C D. Translating the histone code. Science 2001; 293: 1074–1080
   PubMed Web of Science ®Google Scholar
• Rippe K. Dynamic organization of the cell nucleus. Curr Opin Genet Dev 2007; 17: 373–380
   PubMed Web of Science ®Google Scholar
• Wahlfors J, Hiltunen H, Heinonen K, Hamalainen E, Alhonen L, Janne J. Genomic hypomethylation in human chronic lymphocytic leukemia. Blood 1992; 80: 2074–2080
   PubMed Web of Science ®Google Scholar
• Raval A, Byrd J C, Plass C. Epigenetics in chronic lymphocytic leukemia. Semin Oncol 2006; 33: 157–166
   PubMed Web of Science ®Google Scholar
• Plass C, Byrd J C, Raval A, Tanner S M, de la Chapelle A. Molecular profiling of chronic lymphocytic leukaemia: genetics meets epigenetics to identify predisposing genes. Br J Haematol 2007; 139: 744–752
   PubMed Web of Science ®Google Scholar
• Smiraglia D J, Plass C. The study of aberrant methylation in cancer via restriction landmark genomic scanning. Oncogene 2002; 21: 5414–5426
   PubMed Web of Science ®Google Scholar
• Rush L J, Raval A, Funchain P, Johnson A J, Smith L, Lucas D M, et al. Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets. Cancer Res 2004; 64: 2424–2433
   PubMed Web of Science ®Google Scholar
• Hanada M, Delia D, Aiello A, Stadtmauer E, Reed J C. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 1993; 82: 1820–1828
   PubMed Web of Science ®Google Scholar
• Yuille M R, Condie A, Stone E M, Wilsher J, Bradshaw P S, Brooks L, et al. TCL1 is activated by chromosomal rearrangement or by hypomethylation. Genes Chromosomes Cancer 2001; 30: 336–341
   PubMed Web of Science ®Google Scholar
• Raval A, Lucas D M, Matkovic J J, Bennett K L, Liyanarachchi S, Young D C, et al. TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 3877–3885
   PubMed Web of Science ®Google Scholar
• Raval A, Tanner S M, Byrd J C, Angerman E B, Perko J D, Chen S S, et al. Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell 2007; 129: 879–890
   PubMed Web of Science ®Google Scholar
• Mertens D, Wolf S, Schroeter P, Schaffner C, Dohner H, Stilgenbauer S, et al. Down-regulation of candidate tumor suppressor genes within chromosome band 13q14.3 is independent of the DNA methylation pattern in B-cell chronic lymphocytic leukemia. Blood 2002; 99: 4116–4121
   PubMed Web of Science ®Google Scholar
• Mertens D, Wolf S, Tschuch C, Mund C, Kienle D, Ohl S, et al. Allelic silencing at the tumor-suppressor locus 13q14.3 suggests an epigenetic tumor-suppressor mechanism. Proc Natl Acad Sci USA 2006; 103: 7741–7746
   PubMed Web of Science ®Google Scholar
• Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764–1775
   PubMed Web of Science ®Google Scholar
• Orchard J A, Ibbotson R E, Davis Z, Wiestner A, Rosenwald A, Thomas P W, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004; 363: 105–111
   PubMed Web of Science ®Google Scholar
• Rassenti L Z, Huynh L, Toy T L, Chen L, Keating M J, Gribben J G, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004; 351: 893–901
   PubMed Web of Science ®Google Scholar
• Corcoran M, Parker A, Orchard J, Davis Z, Wirtz M, Schmitz O J, et al. ZAP-70 methylation status is associated with ZAP-70 expression status in chronic lymphocytic leukemia. Haematologica 2005; 90: 1078–1088
   PubMed Web of Science ®Google Scholar
• Byrd J C, Shinn C, Ravi R, Willis C R, Waselenko J K, Flinn I W, et al. Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood 1999; 94: 1401–1408
   PubMed Web of Science ®Google Scholar
• Gaidano G, Ballerini P, Gong J Z, Inghirami G, Neri A, Newcomb E W, et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukaemia. Proc Natl Acad Sci USA 1991; 88: 5413–5417
   PubMed Web of Science ®Google Scholar
• Trbusek M, Malcikova J, Smardova J, Kuhrova V, Mentzlova D, Francova H, et al. Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation status and previous treatment. Leukaemia 2006; 20: 1159–1161
   PubMed Web of Science ®Google Scholar
• Schaffner C, Stilgenbauer S, Rappold G A, Döhner H, Lichter P. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukaemia. Blood 1999; 94: 748–753
   PubMed Web of Science ®Google Scholar
• Austen B, Powell J E, Alvi A, Edwards I, Hooper L, Starczynski J, et al. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. Blood 2005; 106: 3175–3182
   PubMed Web of Science ®Google Scholar
• Austen B, Skowronska A, Baker C, Powell J E, Gardiner A, Oscier D, et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol 2007; 25: 5448–5457
   PubMed Web of Science ®Google Scholar
• Grever M R, Lucas D M, Dewald G W, Neuberg D S, Reed J C, Kitada S, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 2007; 25: 799–804
   PubMed Web of Science ®Google Scholar
• Pettitt A R, Sherrington P D, Stewart G, Cawley J C, Taylor A M, Stankovic T. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood 2001; 98: 814–822
   PubMed Web of Science ®Google Scholar
• Damle R N, Wasil T, Fais F, Ghiotto F, Valetto A, Allen S L, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukaemia. Blood 1999; 94: 1840–1847
   PubMed Web of Science ®Google Scholar
• Hamblin T J, Davis Z, Gardiner A, Oscier D G, Stevenson F K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukaemia. Blood 1999; 94: 1848–1854
   PubMed Web of Science ®Google Scholar
• Le Garff-Tavernier M, Ticchioni M, Brissard M, Salmon C, Raynaud S, Davi F, et al. National standardization of ZAP-70 determination by flow cytometry: the French experience. Clin Cytom B 2007; 2: 103–108
   Google Scholar
• Heintel D, Kienle D, Shehata M, Kröber A, Kroemer E, Schwarzinger I, et al. High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia. Leukemia 2005; 19: 1216–1223
   PubMed Web of Science ®Google Scholar
• van't Veer M B, Brooijmans A M, Langerak A W, Verhaaf B, Goudswaard C S, Graveland W J, et al. The predictive value of lipoprotein lipase for survival in chronic lymphocytic leukemia. Haematologica 2006; 91: 56–63
   PubMedGoogle Scholar